Institution · Munich Leukemia Laboratory (Germany)

Most cited papers from Munich Leukemia Laboratory (Germany)

Munich Leukemia Laboratory (Germany)

What are the most cited papers from Munich Leukemia Laboratory (Germany)?

The most cited paper from Munich Leukemia Laboratory (Germany) is "The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms" (Joseph David Khoury et al., 2022), with 4,204 citations. Next come "Frequent pathway mutations of splicing machinery in myelodysplasia" (2,089) and "Landscape of genetic lesions in 944 patients with myelodysplastic syndromes" (1,550).

Published TypeFieldAccessCitations

Showing 50 of 60 papers. Every paper with more than 228 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms Joseph David Khoury et al. · Leukemia Open access	22 Jun 2022	4,204
2	Frequent pathway mutations of splicing machinery in myelodysplasia Kenichi Yoshida et al. · Nature	9 Sep 2011	2,089
3	Landscape of genetic lesions in 944 patients with myelodysplastic syndromes Torsten Haferlach et al. · Leukemia Open access	13 Nov 2013	1,550
4	Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party Gerrit Jan Schuurhuis et al. · Blood Open access	12 Jan 2018	1,054
5	BRAF Mutations in Hairy-Cell Leukemia Enrico Tiacci et al. · New England Journal of Medicine Open access	11 Jun 2011	1,029
6	Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes Peter Valent, Amy D. Klion, Hans‐Peter Horny et al. · Journal of Allergy and Clinical Immunology Open access	28 Mar 2012	774
7	2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party Michael Heuser et al. · Blood Open access	Nov 2021	772
8	Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia Rongqing Aaron Pan et al. · Cancer Discovery Open access	17 Dec 2013	751
9	Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry Alessandro Pastore et al. · The Lancet Oncology	7 Aug 2015	621
10	Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3 –Internal Tandem Duplication Mutation (SORMAIN) Andreas Burchert et al. · Journal of Clinical Oncology Open access	16 Jul 2020	578
11	Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference Peter Valent, Hans‐Peter Horny, John M. Bennett et al. · Leukemia Research	26 Jan 2007	511
12	Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin Ramiro Garzon, Michela Garofalo, Maria Paola Martelli et al. · Proceedings of the National Academy of Sciences Open access	28 Feb 2008	504
13	Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia Lisa Jane Russell et al. · Blood Open access	29 Jul 2009	502
14	Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial Thomas Sonnweber et al. · European Respiratory Journal Open access	10 Dec 2020	452
15	Landscape Of Genetic Lesions In 944 Patients With Myelodysplastic Syndromes Yasunobu Nagata et al. · Blood	15 Nov 2013	431
16	Dynamics of clonal evolution in myelodysplastic syndromes Hideki Makishima et al. · Nature Genetics Open access	19 Dec 2016	428
17	Recurrent SETBP1 mutations in atypical chronic myeloid leukemia Rocco Piazza et al. · Nature Genetics Open access	9 Dec 2012	428
18	Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML) Benjamin Hanfstein et al. · Leukemia	26 Mar 2012	420
19	Prognostic relevance of FLT3-TKD mutations in AML: the combination matters—an analysis of 3082 patients Ulrike Bacher, Claudia Haferlach, Wolfgang Kern et al. · Blood Open access	26 Oct 2007	417
20	New insights to the MLL recombinome of acute leukemias Claus Meyer et al. · Leukemia	5 Mar 2009	412
21	Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms Ayana Kon et al. · Nature Genetics	18 Aug 2013	406
22	Myelodysplastic Cells in Patients Reprogram Mesenchymal Stromal Cells to Establish a Transplantable Stem Cell Niche Disease Unit Hind Medyouf et al. · Cell stem cell Open access	3 Apr 2014	386
23	KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival Susanne Schnittger, Tobias M. Kohl, Torsten Haferlach et al. · Blood Open access	28 Oct 2005	381
24	Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia Chiara Elena et al. · Blood Open access	6 Jul 2016	367
25	Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation Tetsuichi Yoshizato et al. · Blood Open access	21 Feb 2017	359
26	Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma Holly Lee et al. · Nature Medicine Open access	31 Aug 2023	354
27	Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgVH status and immunophenotyping Claudia Haferlach, Frank Dicker, Susanne Schnittger et al. · Leukemia	6 Sep 2007	347
28	Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants for the SAKK and the German CML Study Group et al. · Leukemia Open access	14 Aug 2017	342
29	Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma Matteo Da Vià et al. · Nature Medicine	22 Feb 2021	341
30	Minimal residual disease levels assessed by NPM1 mutation–specific RQ-PCR provide important prognostic information in AML Susanne Schnittger, Wolfgang Kern, Claudia Tschulik et al. · Blood Open access	8 Jul 2009	332
31	EZH2 mutations are frequent and represent an early event in follicular lymphoma Csaba Bödör et al. · Blood Open access	20 Sep 2013	329
32	Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients Ahmet H Elmaagacli, Nina K. Steckel, Michael Koldehoff et al. · Blood	3 May 2011	317
33	Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal Peter Valent et al. · HemaSphere Open access	13 Oct 2021	308
34	SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML) Manja Meggendorfer, Andreas Roller, Torsten Haferlach et al. · Blood Open access	24 Aug 2012	308
35	Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes Utz O. Krug et al. · The Lancet	Dec 2010	307
36	Implications of NRAS mutations in AML: a study of 2502 patients Ulrike Bacher, Torsten Haferlach, Claudia Schoch et al. · Blood	25 Jan 2006	305
37	SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS Luca Malcovati et al. · Blood Open access	29 Apr 2020	302
38	Next-Generation Sequencing Technology Reveals a Characteristic Pattern of Molecular Mutations in 72.8% of Chronic Myelomonocytic Leukemia by Detecting Frequent Alterations in TET2, CBL, RAS, and RUNX1 Alexander Kohlmann, Vera Großmann, Hans‐Ulrich Klein et al. · Journal of Clinical Oncology	20 Jul 2010	294
39	KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis Michel Arock et al. · Leukemia Open access	4 Feb 2015	292
40	Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia Yilong Li et al. · Nature Open access	23 Mar 2014	291
41	Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV Alice Charlotte Fabarius et al. · Blood	29 Oct 2011	291
42	Human-level recognition of blast cells in acute myeloid leukaemia with convolutional neural networks Christian Matek, Simone Schwarz, Karsten Spiekermann et al. · Nature Machine Intelligence Open access	12 Nov 2019	283
43	T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals Nora Philipp et al. · Blood Open access	25 Jul 2022	282
44	Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype Vera Großmann et al. · Blood Open access	20 Oct 2011	270
45	Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia Wolfgang Kern, Daniela Voskova, Claudia Schoch et al. · Blood	30 Jul 2004	269
46	RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis Susanne Schnittger, Frank Dicker, Wolfgang Kern et al. · Blood	10 Dec 2010	266
47	TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups Detlef Haase et al. · Leukemia Open access	11 Jan 2019	264
48	Comprehensive mutational profiling in advanced systemic mastocytosis Juliana Schwaab et al. · Blood	19 Aug 2013	263
49	Landscape of TET2 mutations in acute myeloid leukemia Sandra Weißmann, Tamara Alpermann, Vera Grossmann et al. · Leukemia	25 Nov 2011	261
50	Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome Vikas Madan, Deepika Kanojia, Jia Li et al. · Nature Communications Open access	14 Jan 2015	253

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.